risedronic acid has been researched along with Hyperparathyroidism in 4 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Urinary deoxypyridinoline, a bone resorption marker, decreased by 46." | 2.73 | Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brookler, KH | 1 |
| Sato, Y | 2 |
| Honda, Y | 2 |
| Umeno, K | 1 |
| Hayashida, N | 1 |
| Iwamoto, J | 2 |
| Takeda, T | 1 |
| Matsumoto, H | 1 |
| Reasner, CA | 1 |
| Stone, MD | 1 |
| Hosking, DJ | 1 |
| Ballah, A | 1 |
| Mundy, GR | 1 |
2 trials available for risedronic acid and Hyperparathyroidism
| Article | Year |
|---|---|
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bone Density; Bone Density Conservation Agents; Etidroni | 2011 |
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2007 |
2 other studies available for risedronic acid and Hyperparathyroidism
| Article | Year |
|---|---|
Monaural diplacusis with tinnitus, aural fullness, hyperacusis, and sensorineural hearing loss.
Topics: Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Etidronic Acid; Hearing Loss, Sensorine | 2009 |
Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analysis of Variance; Bone Resorption; Calcium; Et | 1993 |